Pasithea Therapeutics Corp.
KTTA
$0.73
-$0.03-4.38%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.47% | -16.69% | -10.50% | -18.75% | -14.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.84% | -17.37% | -10.82% | 8.51% | 13.28% |
| Operating Income | 18.84% | 17.37% | 10.82% | -8.51% | -13.28% |
| Income Before Tax | 17.80% | 15.50% | 10.34% | -8.45% | -8.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.80% | 15.50% | 10.34% | -8.45% | -8.36% |
| Earnings from Discontinued Operations | -- | -- | -- | 98.87% | 99.11% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.88% | 16.44% | 12.89% | 1.60% | 3.63% |
| EBIT | 18.84% | 17.37% | 10.82% | -8.51% | -13.28% |
| EBITDA | 19.59% | 18.06% | 11.28% | -7.70% | -11.51% |
| EPS Basic | 48.23% | 23.42% | 1.52% | -20.74% | -15.26% |
| Normalized Basic EPS | 48.12% | 22.55% | -1.33% | -42.98% | -39.13% |
| EPS Diluted | 48.23% | 23.42% | 1.52% | -20.74% | -15.26% |
| Normalized Diluted EPS | 48.12% | 22.55% | -1.33% | -42.98% | -39.13% |
| Average Basic Shares Outstanding | 122.10% | 14.88% | -13.95% | -15.09% | -12.10% |
| Average Diluted Shares Outstanding | 122.10% | 14.88% | -13.95% | -15.09% | -12.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |